Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Terminated × HDAC-42 × Clear all

Phase

Phase 2/3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neurofibromatosis 2 1

Interventions

Gemcitabine 8 Cisplatin 7 Carboplatin 7 Paclitaxel 6 Fluorouracil 6 Cyclophosphamide 6 Docetaxel 5 Capecitabine 5 Vinorelbine 3 Stem Cell Transplantation 3 Radiotherapy 3 Pemetrexed 3 Melphalan 3 Leucovorin 3 Granulocyte Colony-Stimulating Factor 3 Filgrastim 3 Etoposide 3 Bevacizumab 3 umbralisib 2 ublituximab 2 fludarabine 2 Trastuzumab 2 Transplantation, Homologous 2 Surveys and Questionnaires 2 S 1 (combination) 2 Oxaliplatin 2 Nivolumab 2 Mitomycin 2 Erlotinib Hydrochloride 2 Drug Therapy 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05130866 2025-10-07

POPLAR-NF2

Recursion Pharmaceuticals Inc.

Phase 2/3 Terminated

Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡